{"filing":{"accession_number":"0001104659-26-089281","cik":"0001818382","ticker":"HUMAW","company_name":"Humacyte, Inc.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"tm2621850d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926089281/tm2621850d1_8k.htm"},"events":[{"id":22475,"run_id":20329,"accession_number":"0001104659-26-089281","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Humacyte received formal notification from Nasdaq on July 31, 2026, that its common stock bid price closed below the $1.00 minimum requirement for 30 consecutive business days, triggering a delisting notice under Nasdaq Listing Rule 5450(a)(1). The company has been granted a 180-calendar-day compliance period (until January 27, 2027) to regain compliance by achieving a closing bid price of $1.00 or more for 10 consecutive business days. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued exchange listing status.","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22427,"accession_number":"0001104659-26-089281","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Humacyte received formal notification from Nasdaq on July 31, 2026, that its common stock bid price closed below the $1.00 minimum requirement for 30 consecutive business days, triggering a delisting notice under Nasdaq Listing Rule 5450(a)(1). The company has been granted a 180-calendar-day compliance period (until January 27, 2027) to regain compliance by achieving a closing bid price of $1.00 or more for 10 consecutive business days. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued exchange listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:26:04.828527+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22427,"accession_number":"0001104659-26-089281","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Humacyte received formal notification from Nasdaq on July 31, 2026, that its common stock bid price closed below the $1.00 minimum requirement for 30 consecutive business days, triggering a delisting notice under Nasdaq Listing Rule 5450(a)(1). The company has been granted a 180-calendar-day compliance period (until January 27, 2027) to regain compliance by achieving a closing bid price of $1.00 or more for 10 consecutive business days. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued exchange listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:26:04.828527+00:00","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-07-31"}]}